This inventor holds 2 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignee: Seikagaku Corporation. Active years: 2013-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013-2014
Title: Innovations by Shigeyuki Wakitani
Introduction
Shigeyuki Wakitani is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of medical diagnostics, particularly in the detection of joint diseases. With a total of 2 patents, his work has the potential to improve the accuracy and sensitivity of joint disease assessments.
Latest Patents
Wakitani's latest patents include a "Method for assaying keratan sulfate" and an "assay kit therefor." This invention provides a method for immunologically determining keratan sulfate levels in biological samples. The method involves using an anti-keratan sulfate monoclonal antibody that exhibits specific reaction characteristics. This allows for the detection of keratan sulfate in samples, which is crucial for diagnosing joint diseases. Additionally, he has developed a "Method of detecting articular cartilage degeneration or damage." This method enables the detection of cartilage damage that may not be visible in radiographs, using keratan sulfate concentration in blood samples as an index.
Career Highlights
Wakitani is associated with Seikagaku Corporation, where he continues to innovate in the field of medical diagnostics. His work has been instrumental in advancing techniques for assessing joint health and disease progression.
Collaborations
Some of his notable coworkers include Hiroshi Fujita and Yasuhiro Kurahashi, who have collaborated with him on various projects.
Conclusion
Shigeyuki Wakitani's contributions to medical diagnostics through his innovative patents highlight the importance of advancements in joint disease detection. His work not only enhances diagnostic accuracy but also paves the way for better treatment options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile